Finerenone

Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) developed primarily for the treatment of chronic kidney disease (CKD) in patients with type 2 diabetes, as well as for heart failure with reduced ejection fraction (HFrEF). It offers greater receptor selectivity and improved safety over traditional steroidal MRAs like spironolactone and eplerenone.

Our Finerenone is produced under GMP-compliant conditions and is suitable for formulation development, research, and global API sourcing.

Applications:

• Treatment of chronic kidney disease in diabetic patients

• Heart failure drug development

• Pharmaceutical formulation and R&D

• Licensed generic production

Packaging:
1g, 10g, 100g, 1kg or customized packaging available

Storage:
Keep tightly sealed, store in a dry and cool place at 2–8°C. Protect from light and moisture.